# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

> **NCT06801509** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 540 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose
- **BIOLOGICAL:** Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose
- **BIOLOGICAL:** Placebo control: Saline
- **BIOLOGICAL:** Shingrix®
- **BIOLOGICAL:** Ganwei®

## Key facts

- **NCT ID:** NCT06801509
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2025-11-10
- **Final completion:** 2027-10-10
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801509, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06801509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*